Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin pharmacokinetics in critically ill adults with invasive candidiasis
NL-OMON32922Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2010
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anidulafungin in invasive candidiasis and invasive mycoses, sponsored by University Medical Center Groningen. Primary endpoint: Correlation between pharmacokinetic parameters and disease severity markers. Started Jun 2010; status: active, not recruiting.
02
Drugs
anidulafungin
03
Conditions
invasive candidiasisinvasive mycoses
Beyond the preview
Go deeper on NL-OMON32922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32922.